
Phosphodiesterase III inhibitors constitute a new therapeutic group for congestive cardiac failure. They inhibit the degradation of cyclic adenosine monophosphate and increase the intracellular calcium. They have a double inotropic and vasodilator haemodynamics occurs without any increase in the myocardial effect. The improvement in the consumption of oxygen. The beneficial haemodynamic effect seems to last over a medium period of time, but the survival in the long term treatment is not yet known.
Electrophysiology, Heart Failure, Oxygen Consumption, Phosphodiesterase Inhibitors, Humans, Kidney
Electrophysiology, Heart Failure, Oxygen Consumption, Phosphodiesterase Inhibitors, Humans, Kidney
| citations The total number of citations received by all articles of the researcher of interest. | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
